Nebenwirkungen · Enbrel
Enbrel 25 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-090271 · Präparat HOS-084041
Serious and fatal infections have been reported during use of Enbrel; reported pathogens include bacteria, mycobacteria (including tuberculosis), viruses and fungi. Some have occurred within a few weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes, congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis (see section 4.4). Enbrel treatment may increase mortality in patients with established sepsis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-13T14:40:00Z · SHA-256 2c6500390fb2c4d6c023708f4ad5e87e0680d81ce838cfcbebc32899e1a4b8e3 · Passage 43a898428c2c0e39ef248ec66521fdb1a4a52191fef7816f55c1f83cfbc87365 · Zeichen 14979–15485 im Abschnitt